Alliance for Aging Research on First 10 Part D Drugs Subject to Medicare Price-Setting: Today is Not a Reason to Celebrate
WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .
- WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .
- Sue Peschin, MHS, President and CEO at the Alliance for Aging Research, issued the following statement in response:
The process instead captures drugs that serve large numbers of beneficiaries at modest cost rather than high-cost drugs. - "Staging a celebration to announce the first 10 Part D drugs subject to CMS' government price-setting in the Medicare program is macabre and misleading.
- We have opposed every Medicare price-setting proposal since 2019 because their value frameworks combine analyses of both cost-effectiveness and budget impact.